What’s Keeping Payers Up at Night?

Home / Intelligence / Webinars / What’s Keeping Payers Up at Night?

Available On Demand

The U.S. market access landscape is becoming increasingly competitive and complex. It is now more important than ever for drug manufacturers to keep abreast of what payers are thinking to maximize the likelihood of receiving favorable reimbursement outcomes.

Through in-depth and ongoing conversations with Pharmacy Benefit Managers (PBMs) and Managed Care Organizations (MCOs), Trinity’s Value, Access and Pricing experts uncover what payers believe to be the most critical factors shaping pricing and market access decision-making for manufacturers over the next 6-24 months.

Key Topics

The impact of biosimilar entry on the pricing and access landscape
The different avenues of reimbursement for high-cost therapies
Social determinants of health (SDOH) and the impact on payers

Complete the form below to view the on-demand webinar.

By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.

Related Intelligence

Briefs

Unlocking Environmental Sustainability Opportunities in the Life Sciences

The healthcare industry has long been known for its significant environmental impact, including contributing ~5% of total global emissions. As awareness of this impact has increased, life sciences companies are now actively committing to climate resilience and environmental sustainability through various initiatives, including net-zero commitments. Trinity Life Sciences has identified several recent trends driving this […]

Briefs

Global Dossiers in the Joint Clinical Assessment Era: Impacts and Implications

Joint clinical assessment (JCA) is a European Union (EU) initiative intended to improve patient access to health technologies in Europe through a harmonized clinical health technology assessment (HTA) process. From January 2025, all new oncology medicines and advanced therapy medicinal products will go through the JCA process, followed by all orphan medicinal products from 2028 […]

Briefs

Assessing the Influence of ICER Reports on U.S. Payer Decision Making

The Institute for Clinical and Economic Review (ICER) is an independent, non-profit research organization dedicated to assessing the value of healthcare interventions, including diagnostics, devices, digital therapeutics and prescription drugs. Although ICER’s assessments do not represent a mandate for product funding or pricing in the U.S. in the same way as, for example, National Institute […]